ADMA Biologics, Inc. logo ADMA - ADMA Biologics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 1
BUY 8
HOLD 1
SELL 0
STRONG
SELL 0
| PRICE TARGET: $18.67 DETAILS
HIGH: $21.00
LOW: $17.00
MEDIAN: $18.00
CONSENSUS: $18.67
UPSIDE: 120.56%

Stock News

ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA BIOLOGICS, INC. Securities Class Action - Contact Levi & Korsinsky

ADMA Shareholder Alert: August 10, 2026 Lead Plaintiff Deadline in ADMA BIOLOGICS, INC. Securities Class Action - Contact Levi & Korsinsky

ADMA Biologics allegedly shipped unwanted ASCENIV inventory to distributors at $900/gram, creating fictitious demand while payors denied reimbursement and providers stopped ordering. ADMA Biologics allegedly shipped unwanted ASCENIV inventory to distributors at $900/gram, creating fictitious demand while payors denied reimbursement and providers stopped ordering.

Jul 27, 2026 06:13 AM • globenewswire.com (Hide legal announcements)
Did You Lose Money Investing in ADMA Biologics, Inc. (ADMA)? Contact Robbins LLP for Information About Recovering Your Losses

Did You Lose Money Investing in ADMA Biologics, Inc. (ADMA)? Contact Robbins LLP for Information About Recovering Your Losses

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired ADMA Biologics, Inc. (NASDAQ: ADMA) securities between August 9,2024 and March 25, 2026. ADMA Biologics, Inc. is a biopharmaceutical company that develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Jul 27, 2026 06:00 AM • globenewswire.com (Hide legal announcements)
ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed

ADMA Alert: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed

SAN FRANCISCO, July 27, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices.

Jul 27, 2026 05:30 AM • prnewswire.com (Hide legal announcements)
ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ADMA DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 27, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 27, 2026 05:28 AM • newsfilecorp.com (Hide legal announcements)
AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit

AUGUST 10, 2026 DEADLINE: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead ADMA Investor Class Action Lawsuit

San Diego, California--(Newsfile Corp. - July 27, 2026) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), have until Monday, August 10, 2026 to seek appointment as lead plaintiff of the ADMA Biologics class action lawsuit. Captioned Mazzarino v.

Jul 27, 2026 04:55 AM • newsfilecorp.com (Hide legal announcements)
$ADMA Lawsuit Notice: BFA Law Reminds ADMA Biologics Investors of August 10 Lead Plaintiff Deadline After 29% Stock Drop Triggers Securities Fraud Class Action

$ADMA Lawsuit Notice: BFA Law Reminds ADMA Biologics Investors of August 10 Lead Plaintiff Deadline After 29% Stock Drop Triggers Securities Fraud Class Action

NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

Jul 27, 2026 03:36 AM • globenewswire.com (Hide legal announcements)
ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

ADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA

LOS ANGELES, July 27, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against ADMA Biologics, Inc. ("ADMA" or "the Company") (NASDAQ: ADMA) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of ADMA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

Jul 27, 2026 12:40 AM • prnewswire.com (Hide legal announcements)
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New York, New York--(Newsfile Corp. - July 26, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ: ADMA) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired ADMA securities between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period").

Jul 26, 2026 08:00 AM • newsfilecorp.com (Hide legal announcements)
ADMA BIOLOGICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

ADMA BIOLOGICS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - July 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Jul 26, 2026 04:52 AM • newsfilecorp.com (Hide legal announcements)
ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

ADMA BIOLOGICS DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

NEW YORK, July 25, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the “Class Period”), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm.

Jul 25, 2026 03:56 PM • globenewswire.com (Hide legal announcements)
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 25, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 25, 2026 02:39 AM • newsfilecorp.com (Hide legal announcements)
ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

ADMA Biologics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ADMA Biologics, Inc. - ADMA

NEW ORLEANS, July 24, 2026 /PRNewswire/ -- - ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against  ADMA Biologics, Inc. (NasdaqGM: ADMA) ("ADMA" or the "Company"), if they purchased or otherwise acquired the Company's securities between August 9, 2024 and March 25, 2026, inclusive (the "Class Period").  This action is pending in the United States District Court for the District of New Jersey.

Jul 24, 2026 06:00 PM • prnewswire.com (Hide legal announcements)
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

New York, New York and New Orleans, Louisiana--(Newsfile Corp. - July 24, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in ADMA Biologics, Inc. ("ADMA" or the "Company") (NASDAQ: ADMA) of a class action securities lawsuit.

Jul 24, 2026 01:14 PM • newsfilecorp.com (Hide legal announcements)
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

LOS ANGELES, July 24, 2026 (GLOBE NEWSWIRE) -- Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming August 10, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired ADMA Biologics, Inc. (“ADMA” or the “Company”) (NASDAQ: ADMA) securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).

Jul 24, 2026 11:41 AM • globenewswire.com (Hide legal announcements)
ADMA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

ADMA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA

New York, New York--(Newsfile Corp. - July 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ADMA Biologics, Inc. (NASDAQ: ADMA) between August 9, 2024 and March 25, 2026, both dates inclusive (the "Class Period"), of the important August 10, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased ADMA Biologics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Jul 24, 2026 11:18 AM • newsfilecorp.com (Hide legal announcements)
ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS

ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit– HBSS

SAN FRANCISCO, July 24, 2026 (GLOBE NEWSWIRE) -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices.

Jul 24, 2026 09:58 AM • globenewswire.com (Hide legal announcements)
ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS

ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- HBSS

SAN FRANCISCO, July 24, 2026 /PRNewswire/ -- Hagens Berman alerts investors in ADMA Biologics, Inc. (NASDAQ: ADMA) that a securities fraud class action lawsuit has been filed. The lawsuit focuses on alleged misrepresentations concerning the company's financial condition, revenue recognition, inventory distribution, and business practices.

Jul 24, 2026 04:00 AM • prnewswire.com (Hide legal announcements)
$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

$ADMA Fraud Notification: ADMA Biologics Sued for Fraud Over Misrepresentations about Channel Stuffing – Investors Notified to Contact BFA Law

NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against ADMA Biologics, Inc. (NASDAQ:ADMA) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/adma-biologics-class-action-lawsuit.

Jul 24, 2026 02:34 AM • globenewswire.com (Hide legal announcements)
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In ADMA Biologics To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in ADMA Biologics between August 9, 2024 and March 25, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] New York, New York--(Newsfile Corp. - July 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against ADMA Biologics, Inc. ("ADMA Biologics" or the "Company") (NASDAQ: ADMA) and reminds investors of the August 10, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Jul 23, 2026 04:26 PM • newsfilecorp.com (Hide legal announcements)

Price Targets